LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.78 -0.21

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.75

Max

4.89

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+24.04% upside

Turustatistika

By TradingEconomics

Turukapital

92M

593M

Eelmine avamishind

4.99

Eelmine sulgemishind

4.78

Uudiste sentiment

By Acuity

17%

83%

22 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. dets 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. dets 2025, 23:51 UTC

Tulu

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. dets 2025, 23:39 UTC

Suurimad hinnamuutused turgudel

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. dets 2025, 21:40 UTC

Tulu

Nike Sales Tick Up, But China Weakness Persists

18. dets 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. dets 2025, 23:37 UTC

Market Talk
Tulu

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. dets 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. dets 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. dets 2025, 22:58 UTC

Omandamised, ülevõtmised, äriostud

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. dets 2025, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. dets 2025, 22:55 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:59 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. dets 2025, 21:35 UTC

Tulu

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. dets 2025, 21:31 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev Down 17% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q EPS 53c >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Apparel Rev $3.91B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Equipment Rev $550M >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q N Amer Rev $5.63B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Footwear Rev $7.66B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev $1.42B >NKE

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

24.04% tõus

12 kuu keskmine prognoos

Keskmine 5.83 USD  24.04%

Kõrge 7.5 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

22 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat